http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009150194-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ee21c0ae9cc7d76c89719783979af96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b9f9ff1953e160491141d1cc65cedcd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_357d0763291b1c6f7c199400ca75c394
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f69ac4a45608a1d500f91fcdf8a0b6b4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
filingDate 2009-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08ea8796ebf1cc12a012084fd7ca0025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_402581172db79976a7a9000d8a29e331
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f36f5c48bd0ebaadcfc5f2cd5e4e8cc2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c2897cc88fb7a87624ad33f761dec74
publicationDate 2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2009150194-A1
titleOfInvention Telaprevir dosing regimen
abstract This invention relates to the use of specific dosing regimens of telaprevir in combination with peg-IFN and RBV in the treatment of HCV patients, wherein the treatment comprises (a) a lead-in phase of administering to the subject pegylated interferon and ribavirin, and (b) a treatment phase of administering to the subject a combination of telaprevir, pegylated interferon and ribavirin.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8993578-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8809265-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8853176-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9452194-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8466159-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8969357-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11192914-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8680106-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010093843-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8492386-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8685984-B2
priorityDate 2008-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007109604-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID11103
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128231682
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453047453
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID37542
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45051774
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419480353
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393829
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3010818
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID164825
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422600808
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395848
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507729
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID11103
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16130922

Total number of triples: 58.